Skip to main content
OpenTrials
Completed

NCT Number: NCT00406991

Retinal Blood Flow and Microthrombi in Type 1 Diabetes

The project aims to find mechanisms for the abnormal retinal blood flow that in diabetic patients often precedes any evidence of clinical retinopathy and may contribute to the development of retinopathy.

Specifically, the projects tests the hypothesis that reduced retinal blood flow found in young patients with type 1 diabetes reflects increased resistance in the small vessels of the retina caused by the formation of small blood clots, called microthrombi; and that antiplatelet agents normalize the reduced retinal blood flow.

Completed

Looking for future studies?

Notify Me

Key information

Age range

18 year–45 year

Sex eligibility

All sexes

Study type

Interventional

Phase

Phase 2

Primary location

Schepens Eye Research Institute

Boston, Massachusetts, 02114, United States

About this study

The ultimate goal of this research is to contribute to the development of strategies to prevent diabetic retinopathy. This project will test the hypothesis that antiplatelet agents normalize the reduced blood flow observed early in the course of type 1 diabetes. If the hypothesis is proven correct, the results will indicate that the formation of small blood clots (microthrombi) occurs early in diabetic retinal vessels. In turn, because microthrombosis could readily account for the occlusive microangiopathy that causes the sight-threatening stages of diabetic retinopathy, the results will propose the desirability of antiplatelet therapy for the prevention of diabetic retinopathy.

We have three specific aims:

  • To confirm that, under basal conditions, retinal blood flow measured with the laser Doppler method in a group of type 1 diabetic patients with no or minimal retinopathy differs from the flow measured in age- and sex-matched nondiabetic control subjects;
  • To determine whether the response of retinal blood flow to low-dose aspirin (81 mg/day) administered for 2 months versus placebo, differs between type 1 diabetic patients with no or minimal retinopathy and age- and sex-matched nondiabetic control subjects;
  • To determine whether in type 1 diabetic patients with no or minimal retinopathy the response of retinal blood flow to low-dose aspirin differs from the response to clopidogrel, a drug that interferes with platelet function downstream of the site of aspirin action.

Who can participate

Healthy volunteers accepted: Yes

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Age 18-45 years,
  • type 1 diabetes duration 1-15 years,
  • absent or minimal retinopathy (EDTRS 20).
  • Age- and gender-matched healthy controls

Exclusion criteria

  • smoking,
  • systemic diseases other than diabetes,
  • retinal diseases other than diabetic retinopathy,
  • pregnancy,
  • bleeding disorders,
  • aspirin allergy,
  • use of anti-platelet agents,
  • non-steroidal anti-inflammatory agents,
  • angiotensin converting enzyme inhibitors,
  • angiotensin receptor antagonists,
  • Vitamin E in large doses.

Treatment and study plan

Aspirin

Drug

clopidogrel

Drug

Primary outcomes

  1. Retinal blood flow

Secondary outcomes

  1. Retinal arterial blood speed

  2. Retinal arterial diameter

Sponsors and collaborators

Lead sponsor

Schepens Eye Research Institute

Other

Registry information

Important dates

Study start
2003
Study completion
2006
First posted
Dec 4, 2006
Registry last updated
Oct 30, 2015

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.